Royalty Pharma (RPRX) Market Capitalization (2020 - 2026)
Powered by 
Analysis
Royalty Pharma (RPRX) Market Capitalization (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 10 | Incyte | 25.65 Bn | 21.11 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 32.24 Bn |
| Mar 31, 2026 | 27.64 Bn |
| Dec 31, 2025 | 22.30 Bn |
| Sep 30, 2025 | 20.43 Bn |
| Jun 30, 2025 | 21.01 Bn |
| Mar 31, 2025 | 17.63 Bn |
| Dec 31, 2024 | 15.03 Bn |
| Sep 30, 2024 | 16.67 Bn |
| Jun 30, 2024 | 15.67 Bn |
| Mar 31, 2024 | 18.14 Bn |
| Dec 31, 2023 | 16.78 Bn |
| Sep 30, 2023 | 16.24 Bn |
| Jun 30, 2023 | 18.50 Bn |
| Mar 31, 2023 | 21.88 Bn |
| Dec 31, 2022 | 24.00 Bn |
| Sep 30, 2022 | 24.40 Bn |
| Jun 30, 2022 | 25.53 Bn |
| Mar 31, 2022 | 23.66 Bn |
| Dec 31, 2021 | 24.20 Bn |
| Sep 30, 2021 | 21.94 Bn |